Which has the lower trailing P/E, COR or TEVA?

COR has the lower trailing P/E: COR trades at 23.89 and TEVA at 61.82. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, COR or TEVA?

Over the past five years, COR grew revenue faster — COR at a 10.25% CAGR versus TEVA at 1.19%.

Does COR or TEVA pay a bigger dividend?

COR pays a dividend (0.75% yield), while TEVA is a former payer with no current dividend run rate.

Is COR or TEVA more profitable?

TEVA runs the higher net margin — COR at 0.79% versus TEVA at 4.08%.

How have COR and TEVA total returns compared?

Over the past 10 years, COR delivered 16.40% and TEVA delivered -2.64% annualized total return. Past performance doesn't predict future results.

Cencora, Inc. (COR) vs Teva Pharmaceutical Industries Limited (TEVA)

A side-by-side comparison of Cencora, Inc. and Teva Pharmaceutical Industries Limited across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of September 11, 2026. Differences are shown without an overall score or investment verdict.

COR

Cencora, Inc.

$62.57B

$321.57HealthcareDelayed quote: Sep 11, 2026, 4:00 PM EDT

TEVA

Teva Pharmaceutical Industries Limited

$43.20B

$37.09HealthcareDelayed quote: Sep 11, 2026, 4:00 PM EDT

Total return — COR vs TEVA

growth of $100 · dividends reinvested · last 10y

COR +351.5% (+16.3%/yr)TEVA -24.2% (-2.7%/yr)COR compounded faster over this window

Log scale — wide-divergence pair

COR TEVA

COR vs TEVA: by the numbers

•COR is the larger company ($62.57B vs $43.20B market cap).
•COR trades at the lower trailing earnings multiple (23.89 vs 61.82 P/E), one valuation lens rather than an overall verdict.
•TEVA converts more revenue to profit (4.08% vs 0.79% net margin).
•COR grew revenue faster over the past five years (10.25% vs 1.19% CAGR).
•COR pays a dividend (0.75% yield), while TEVA is a former payer with no current dividend run rate.

Metrics side by side

Valuation

Metric	COR	TEVA
P/E ratio	23.89	61.82
Forward P/E	17.99	18.72
P/S ratio	0.19	2.49
P/B ratio	20.51	5.57
EV / EBITDA	13.27	18.98
FCF yield	6.49%	3.12%

Profitability

Metric	COR	TEVA
Gross margin	3.71%	52.47%
Operating margin	1.30%	11.45%
Net margin	0.79%	4.08%
ROE	86.03%	9.10%
ROIC	12.75%	6.79%

Dividends

Metric	COR	TEVA
Dividend yield	0.75%	N/A
Payout ratio	17.83%	N/A

Growth (annualized)

Metric	COR	TEVA
Revenue CAGR (5Y)	10.25%	1.19%
EPS CAGR (5Y)	11.97%	N/A
FCF CAGR (5Y)	9.63%	14.58%
Total return CAGR (5Y)	22.92%	31.85%

Frequently asked

Which has the lower trailing P/E, COR or TEVA?: COR has the lower trailing P/E: COR trades at 23.89 and TEVA at 61.82. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, COR or TEVA?: Over the past five years, COR grew revenue faster — COR at a 10.25% CAGR versus TEVA at 1.19%.
Does COR or TEVA pay a bigger dividend?: COR pays a dividend (0.75% yield), while TEVA is a former payer with no current dividend run rate.
Is COR or TEVA more profitable?: TEVA runs the higher net margin — COR at 0.79% versus TEVA at 4.08%.
How have COR and TEVA total returns compared?: Over the past 10 years, COR delivered 16.40% and TEVA delivered -2.64% annualized total return. Past performance doesn't predict future results.

Go deeper

Full COR analysis Full TEVA analysis Interactive comparison tool

Dig into the metrics

Cencora P/E ratio Teva Pharmaceutical Industries P/E ratio Cencora dividend yield Cencora ROE Teva Pharmaceutical Industries ROE Cencora operating margin Teva Pharmaceutical Industries operating margin Cencora revenue growth Teva Pharmaceutical Industries revenue growth Cencora free cash flow Teva Pharmaceutical Industries free cash flow

Cencora & Teva Pharmaceutical Industries appear in these rankings

Highest ROE Stocks Highest FCF Yield Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified September 11, 2026.